Trial Profile
Safety and Immunogenicity of a Clostridium Difficile Toxoid Vaccine Administered to Healthy Adult Subjects Aged 40 to 75 Years in Japan
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jul 2014
Price :
$35
*
At a glance
- Drugs Clostridium difficile vaccine (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 12 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Jul 2013 New trial record